Compare iShares Gold Trust (IAU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Novo Nordisk A/S — how do they compare? iShares Gold Trust trades at $78.88 (market cap $61.51B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.7× iShares Gold Trust's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Novo Nordisk A/S for 116 Days on average.
| IAU | NVO | |
|---|---|---|
Market Cap | $61.51B | $165.31B |
Volume | 3,206,729 | 11,432,838 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $63.98 |
52-Week Low | $74.21 | $35.29 |
Typical Hold Time | 49 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU is trading at $78.60, up 2.0% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $78-$79, with support at $76-$77. Recent news highlights sensitivity to interest rate expectations and Treasury yields, with gold's performance influencing sentiment. Financial ratios are currently unavailable for analysis.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from rising yields. Investment opportunities may arise if the stock holds key support levels amid potential Fed policy shifts, but risks include further downside if rate-hike fears persist or economic data weakens gold's appeal.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
